In a melanoma cell panel, salubrinal combined with 40 μM 4E1RCat reduced 72-hour MTS viability more than either agent alone. The authors reported synergy across the tested melanoma lines, with less effect on FF2441 fibroblasts. Single-agent responses varied by cell line. [2]
Short-term salubrinal treatment reduced amyloid-β-induced injury in primary rat cortical neurons. At 6 h, this response occurred without increased eIF2α phosphorylation or reversal of BiP/PDI elevations. A separate 48-hour Tg2576-neuron experiment instead found increased BACE1 and secreted amyloid-β40, emphasizing the dependence of the response on model, exposure and endpoint. [3,1]
Salubrinal and 4E1RCat in melanoma cell viability
Cell-based study · Human melanoma C8161.Cl9 and MelJuSo (BRAF wild type), UACC 903, A375M and 1205 Lu (BRAF V600E); FF2441 normal human fibroblast comparator [2]
The combination reduced melanoma MTS viability more than either agent alone. Authors report synergy across melanoma lines; responses to single agents varied by cell line. FF2441 fibroblasts were less affected under these conditions.
Literature-Reported Treatment Conditions
- Treatment concentration
- Salubrinal 0–50 μM; combination paired with 40 μM 4E1RCat
- Exposure duration
- 72 h
- Method
- MTS viability assay
- Vehicle
- DMSO
- Co-treatment
- 4E1RCat; single-agent and DMSO comparator arms included
- Reported limits
- Figure 1 does not state replicate n; error bars are SEM. No IC50 was determined for this extraction.
Methods and source locations
Compound reported in the paper: Salubrinal; Compound label in the paper: Sal
Results concern the material and model reported by these authors. No Adooq lot validation, salt conversion or stereochemical equivalence is established.
Figure 1A–C; Determination of Cell Viability; Cell Line and Culture Conditions; first Results subsection
MTS viability relative to control: MTS absorbance; points represent average ± SEM. Qualitative extraction from viewed curves; exact percentages not digitized. — Figure 1A–C and caption; first Results subsection
Combination index: Chou–Talalay/CalcuSyn; authors define CI < 0.9 as synergistic, 0.9–1.1 additive and >1.1 antagonistic. No individual CI decimal inferred from scatter plots. — Figure 1 caption; Determination of Cell Viability
Short-term salubrinal in amyloid-challenged primary neurons
Cell-based study · Primary cortical neurons from E17 rat embryos; 14 DIV in Results 3.1 [3]
Salubrinal attenuated Aβ1-42-induced caspase-3 activation and TUNEL positivity and improved WST-8 viability. At 6 h it did not reverse Aβ-induced BiP/PDI elevations or increase eIF2α phosphorylation, limiting attribution of this short-term response to ER-stress inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μM salubrinal for immunoblots/TUNEL; Figure 1C salubrinal titration 0–100 μM
- Exposure duration
- 3 and 6 h caspase-3 assessment; 6 h TUNEL/WST-8 and ER-marker assessment
- Method
- Addition to neuronal culture
- Co-treatment
- Aβ1-42 25 μM; untreated, salubrinal-alone and Aβ-alone comparators for immunoblot/TUNEL
- Reported limits
- Vehicle is not stated in selected Methods. Figure 1 reports n = 3 but does not define the biological/technical replicate unit.
Methods and source locations
Compound reported in the paper: Salubrinal; Compound label in the paper: salubrinal
Results concern the material and model reported by these authors. No Adooq lot validation, salt conversion or stereochemical equivalence is established.
Figures 1A–C and 3A; Methods 2.1–2.4, 2.7, 2.9; Results 3.1 and 3.3
Cleaved caspase-3, TUNEL-positive neurons and WST-8 viability: Western blot with β-actin, TUNEL/DAPI and WST-8; n = 3, mean ± SEM under shared statistical methods. No exact bar values digitized. — Figure 1A–C and caption; Results 3.1
BiP, PDI and phospho-/total eIF2α at 6 h: Immunoblot; Figure 3A representative blots, β-actin loading control. No formal equivalence test or exact fold change reported for this panel. — Figure 3A and caption; Results 3.3
Longer salubrinal exposure increases BACE1 and secreted amyloid-β
Cell-based study · Primary cortical Tg2576 mouse neurons expressing human APPsw; E15.5 embryos, 7 DIV before treatment [1]
At 48 h, salubrinal increased phospho-eIF2α/total eIF2α and endogenous BACE1, with increased conditioned-medium human Aβ40. This is limiting evidence for interpreting sustained eIF2α phosphorylation as uniformly protective.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 or 80 μM
- Exposure duration
- 48 h
- Method
- Added to glucose-containing neuronal culture medium
- Reported limits
- Selected text does not specify the solvent/vehicle for salubrinal. Control is normal glucose-containing medium. n = 4 in Figure 4D–F; replicate unit not further defined there.
Methods and source locations
Compound reported in the paper: Salubrinal; Compound label in the paper: salubrinal
Results concern the material and model reported by these authors. No Adooq lot validation, salt conversion or stereochemical equivalence is established.
Figure 4D–F and caption; Selective Inhibition of eIF2α Dephosphorylation Increases BACE1 Level and Aβ production in Tg2576 Primary Neurons; Neuronal Cultures; Immunoblot Analysis; Human Aβ40 ELISA; Statistical analysis
Phospho-eIF2α/total eIF2α and BACE1 protein: Immunoblot; BACE1 normalized to β-actin and phospho-eIF2α to total eIF2α; n = 4, mean ± SEM; UV-treated 293 lysate used as phospho-eIF2α positive control. No exact fold changes digitized. — Figure 4D/E and caption
Secreted human Aβ40 per total cellular protein: Human Aβ40-specific ELISA of conditioned medium; n = 4, mean ± SEM; shared methods specify two-tailed t-test versus control. Exact values taken from Results prose, with figure inspected. — Figure 4F; Results subsection Selective Inhibition of eIF2α Dephosphorylation Increases BACE1 Level and Aβ production in Tg2576 Primary Neurons